‘Godzilla’ of weight-loss drugs could provide other important health benefits
Retatrutide, an experimental triple-agonist drug from Eli Lilly, has demonstrated the ability to reduce body weight by up to 25% in trials. The medication targets three hormone pathways: GLP-1, GIP, and glucagon. In addition to weight reduction, phase 3 trial data indicates the drug improves blood sugar levels and reduces inflammation in adults with obesity and type 2 diabetes. While not yet approved by any regulatory agency, the drug is described as a potential new high-water mark for obesity treatments due to its multi-hormone mechanism.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Retatrutide mimics three gut hormones: GLP-1, GIP, and glucagon.
- ✓ Trial participants lost up to 25% of their body weight.
- ✓ The drug delivered A1C reduction and improved blood sugar levels in people with type 2 diabetes.
- ✓ Retatrutide is not yet approved by any regulatory agency.
What changed
Phase 3 trial results for retatrutide show weight loss of up to 25% and improvements in blood sugar and inflammation.
Live updates
-
Eli Lilly experimental drug retatrutide shows weight loss up to 25%
Retatrutide, an experimental triple-agonist drug from Eli Lilly, has demonstrated the ability to reduce body weight by up to 25% in trials. The medication targets three hormone pathways: GLP-1, GIP, and glucagon. In addition to weight reduction, phase 3 trial data indicates the drug improves blood sugar levels and reduces inflammation in adults with obesity and type 2 diabetes. While not yet approved by any regulatory agency, the drug is described as a potential new high-water mark for obesity treatments due to its multi-hormone mechanism.
Why it matters
Most existing weight-loss drugs like Wegovy primarily target the GLP-1 hormone. Retatrutide differs by mimicking three gut hormones to control metabolism, appetite, and blood sugar. This approach aims to provide greater efficacy for patients with type 2 diabetes, who often lose less weight on current medications.
What is confirmed
- Retatrutide mimics three gut hormones: GLP-1, GIP, and glucagon.
- Trial participants lost up to 25% of their body weight.
- The drug delivered A1C reduction and improved blood sugar levels in people with type 2 diabetes.
- Retatrutide is not yet approved by any regulatory agency.
- Phase 3 trials showed the drug reduced inflammation markers in adults with obesity and type 2 diabetes.
Still unconfirmed
- The drug could be effective for treating osteoarthritis and sleep apnea.
What to watch next
- Regulatory approval filings with health agencies
- Publication of full safety profiles from phase 3 trials
confidence 90%Sources used for this update (15)
- Ars Technica — Most powerful obesity drug yet: People lost up to 25% of weight in trial
- The Guardian — ‘Godzilla’ of weight-loss drugs could provide other important health benefits
- Reuters — Lilly's experimental drug cuts weight by 21% in diabetes trial
- Scientific American — Blockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs
- NBC News — People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug
- Eli Lilly — Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
- www.theguardian.com — ‘Godzilla’ of weight-loss drugs could provide other important ...
- www.yahoo.com — ‘Astonishing’ fat jab combination causes record weight loss
- www.news9live.com — ‘Godzilla’ of weight-loss drugs? Retatrutide linked to major ...
- article.wn.com — ‘Godzilla’ of weight-loss drugs could provide other important ...
- www.dailymail.com — 'Godzilla' fat jab retatrutide sheds more fat than Mounjaro ...
- www.timesnownews.com — New Godzilla Weight-Loss Drug Could Help You Lose 2X More ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community